Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers

Fig. 4

Effects of all the CGRP mAbs on MMDs. A Temporal profile of MMDs in patients treated with any CGRP mAb (n = 68). Data are shown as mean ± SD. Statistical analysis was performed using the Kruskal–Wallis test with Dunn’s post hoc test. ***p < 0.001, ****p < 0.0001. B 50%, 75%, and 100% RRs at V1, V2, and V3

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us